Herzog Fox & Neeman Represents Entera Bio in $270m Amgen Licensing Deal
11 December 2018
Herzog Fox & Neeman Partners Yair Geva, Tomer Farkash, Dan Sharot, and Ofer Granot, together with Associate Michal Shirin, represented Israeli biopharmaceutical company Entera Bio in a $270 million research collaboration and licensing agreement deal with California-based, biopharmaceutical company Amgen Inc.
Entera will use its proprietary drug delivery platform to develop oral formulations for one preclinical large molecule program that Amgen has selected. Amgen also has an option to select up to two additional programs to include in the collaboration.
Click here for further reading.